These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26253333)

  • 21. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.
    Day JS; Ding M; Bednarz P; van der Linden JC; Mashiba T; Hirano T; Johnston CC; Burr DB; Hvid I; Sumner DR; Weinans H
    J Orthop Res; 2004 May; 22(3):465-71. PubMed ID: 15099622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
    Panico A; Lupoli GA; Marciello F; Lupoli R; Cacciapuoti M; Martinelli A; Granieri L; Iacono D; Lupoli G
    Med Sci Monit; 2011 Aug; 17(8):CR442-448. PubMed ID: 21804463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities].
    Kaga Y; Ishii S; Kuroda I; Kamiya Y; Nakamura K; Kanemura H; Sugita K; Aihara M
    No To Hattatsu; 2017 Mar; 49(2):113-9. PubMed ID: 30113151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats.
    Shahnazari M; Yao W; Dai W; Wang B; Ionova-Martin SS; Ritchie RO; Heeren D; Burghardt AJ; Nicolella DP; Kimiecik MG; Lane NE
    Bone; 2010 May; 46(5):1267-74. PubMed ID: 19931661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of collagen quality associated with non-enzymatic cross-links in human bone using Fourier-transform infrared imaging.
    Schmidt FN; Zimmermann EA; Campbell GM; Sroga GE; Püschel K; Amling M; Tang SY; Vashishth D; Busse B
    Bone; 2017 Apr; 97():243-251. PubMed ID: 28109917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
    Katayama K; Matsuno T
    Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanical evaluation of bone samples following alendronate therapy in healthy male dogs.
    Fischer KJ; Vikoren TH; Ney S; Kovach C; Hasselman C; Agrawal M; Rubash H; Shanbhag AS
    J Biomed Mater Res B Appl Biomater; 2006 Jan; 76(1):143-8. PubMed ID: 16047323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the effects of x-ray irradiation on the hierarchical structure and mechanical properties of human cortical bone.
    Barth HD; Zimmermann EA; Schaible E; Tang SY; Alliston T; Ritchie RO
    Biomaterials; 2011 Dec; 32(34):8892-904. PubMed ID: 21885114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term experience with alendronate in the treatment of osteoporosis.
    Hochberg MC; Rizzoli R
    Expert Opin Pharmacother; 2006 Jun; 7(9):1201-10. PubMed ID: 16732706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insights into the bisphosphonate holiday: a preliminary FTIRI study.
    Boskey AL; Spevak L; Ma Y; Wang H; Bauer DC; Black DM; Schwartz AV
    Osteoporos Int; 2018 Mar; 29(3):699-705. PubMed ID: 29204959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Is SSBT associated with atypical femoral fracture? SSBT is associated with atypical femoral fracture - pathophysiology of atypical femoral fractures - ].
    Mashiba T
    Clin Calcium; 2012 Jun; 22(6):914-8. PubMed ID: 22653033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
    Chiu WY; Lee JJ; Tsai KS
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
    Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
    J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.
    Mashiba T; Turner CH; Hirano T; Forwood MR; Johnston CC; Burr DB
    Bone; 2001 May; 28(5):524-31. PubMed ID: 11344052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate-treated individuals in low- and high energy fracture conditions.
    Zimmermann EA; Schaible E; Gludovatz B; Schmidt FN; Riedel C; Krause M; Vettorazzi E; Acevedo C; Hahn M; Püschel K; Tang S; Amling M; Ritchie RO; Busse B
    Sci Rep; 2016 Feb; 6():21072. PubMed ID: 26879146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.